Selim Bölükbaşı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Selim Bölükbaşı has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Burak Erden
Department of Ophthalmology, University of Health Sciences, Okmeydani Training and Research Hospital, Istanbul, Turkey
11 shared publications Akin Cakir
Department of Ophthalmology, University of Health Sciences, Okmeydani Training and Research Hospital, Istanbul, Turkey
6 shared publications- Akın Çakır
University of Health Sciences Türkiye, İstanbul Prof. Dr. Cemil Taşcıoğlu City Hospital, Clinic of Ophthalmology, İstanbul, Türkiye
6 shared publications - Mustafa Nuri Elçioğlu
University of Health Sciences Türkiye, İstanbul Prof. Dr. Cemil Taşcıoğlu City Hospital, Clinic of Ophthalmology, İstanbul, Türkiye
5 shared publications Burak Erden
Turkiye Cumhuriyeti Saglik Bakanligi Okmeydani Egitim ve Arastirma Hastanesi
3 shared publicationsGamze Karatas
Department of Ophthalmology, University of Health Sciences, Okmeydani Training and Research Hospital, Istanbul, Turkey
3 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Springer Nature in Ophthalmology and Therapy
Intravitreal Faricimab for Retinal Vein Occlusion: Real-World Outcomes from the Multicenter FARTURK-RVO Study in Türkiye
The aim of this study was to evaluate the real-world efficacy and safety of intravitreal faricimab for macular edema (ME) secondary to retinal vein occlusion (RVO) across a multicenter cohort with up to 52 weeks of follow-up. Data from 17 centers across Türkiye were retrospectively analyzed between 22 November 2024 and 1 March 2026. Patients with branch RVO (BRVO) or central RVO (CRVO) complicated by ME who received at least one intravitreal faricimab injection and had complete ophthalmic and optical coherence tomography (OCT) data with a minimum 4-week follow-up were included. Demographics, diagnosis, prior treatments, best-corrected visual acuity (BCVA; decimal converted to logMAR), central macular thickness (CMT), intraocular pressure (IOP), injection number, follow-up duration, and ocular/systemic adverse events were recorded at baseline, day 7, monthly after each of the first three injections, and at the final visit. A total of 70 patients (37 BRVO [52.9%], 33 CRVO [47.1%]) were included, with a mean follow-up of 23.69 ± 8.54 weeks; 44 (62.8%) were treatment-naïve and 26 (37.2%) were switch patients. When comparing baseline and final visits, treatment-naïve patients showed a mean CMT reduction of 306.9 ± 231.3 µm (from 594.1 ± 206.9 µm at baseline to 287.2 ± 89.9 µm at final visit; p < 0.001), while switch patients demonstrated a mean CMT reduction of 290.6 ± 114.3 µm (from 562.1 ± 107.3 to 271.5 ± 90.7 µm; p < 0.001). The mean logMAR BCVA gain was 0.77 (p < 0.001) in naïve and 0.38 (p < 0.001) in switch patients. IOP remained stable throughout, and no serious ocular or systemic adverse events were recorded. Faricimab demonstrated rapid anatomical and functional improvements in the RVO cohort, evident as early as day 7 after the initial injection. These findings support faricimab as a potent and reliable therapeutic option across both RVO subtypes in routine clinical practice.
- 23 June 2026
- Published by Springer Nature in Ophthalmology and Therapy
Open AccessIntravitreal Faricimab for Retinal Vein Occlusion: Real-World Outcomes from the Multicenter FARTURK-RVO Study in Türkiye
The aim of this study was to evaluate the real-world efficacy and safety of intravitreal faricimab for macular edema (ME) secondary to retinal vein occlusion (RVO) across a multicenter cohort with up to 52 weeks of follow-up. Data from 17 centers across Türkiye were retrospectively analyzed between 22 November 2024 and 1 March 2026. Patients with branch RVO (BRVO) or central RVO (CRVO) complicated by ME who received at least one intravitreal faricimab injection and had complete ophthalmic and optical coherence tomography (OCT) data with a minimum 4-week follow-up were included. Demographics, diagnosis, prior treatments, best-corrected visual acuity (BCVA; decimal converted to logMAR), central macular thickness (CMT), intraocular pressure (IOP), injection number, follow-up duration, and ocular/systemic adverse events were recorded at baseline, day 7, monthly after each of the first three injections, and at the final visit. A total of 70 patients (37 BRVO [52.9%], 33 CRVO [47.1%]) were included, with a mean follow-up of 23.69 ± 8.54 weeks; 44 (62.8%) were treatment-naïve and 26 (37.2%) were switch patients. When comparing baseline and final visits, treatment-naïve patients showed a mean CMT reduction of 306.9 ± 231.3 µm (from 594.1 ± 206.9 µm at baseline to 287.2 ± 89.9 µm at final visit; p < 0.001), while switch patients demonstrated a mean CMT reduction of 290.6 ± 114.3 µm (from 562.1 ± 107.3 to 271.5 ± 90.7 µm; p < 0.001). The mean logMAR BCVA gain was 0.77 (p < 0.001) in naïve and 0.38 (p < 0.001) in switch patients. IOP remained stable throughout, and no serious ocular or systemic adverse events were recorded. Faricimab demonstrated rapid anatomical and functional improvements in the RVO cohort, evident as early as day 7 after the initial injection. These findings support faricimab as a potent and reliable therapeutic option across both RVO subtypes in routine clinical practice.
- 10 March 2020
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 39 (2) , 115-121
Retinal structural changes in patients receiving tamoxifen therapy by spectral-domain optical coherence tomography
Purpose: To evaluate choroidal thickness, ganglion cell complex (GCC) and photoreceptor outer segment (PROS) length were measured in patients with breast cancer undergoing tamoxifen therapy, using spectral-domain optical coherence tomography (SD-OCT); results were compared with those for normal eyes. Materials and Methods: Forty-four patients with breast cancer, undergoing tamoxifen therapy, and 41 healthy controls were included in this prospective, comparative study. All participants underwent a complete ophthalmologic evaluation and SD-OCT. Subfoveal, nasal (nasal distance to fovea 500, 1000, 1500 μm), and temporal (temporal distance to fovea 500, 1000, 1500 μm) choroidal thickness measurements were performed using the enhanced depth imaging mode of SD-OCT. Using an Early Treatment Diagnostic Retinopathy Study (ETDRS) circle at the macular level, the automated retinal segmentation software was applied to determine the thickness of the GCC. PROS length was determined manually, as the distance from the inner surface of the ellipsoid zone to the inner surface of retina pigment epithelium. Results: The mean choroidal thickness was statistically greater in the tamoxifen group than controls in all quadrants (p < 0.001 for all quadrants). Of all tamoxifen users (44 eyes of 44 patients), 33 eyes (75%) had uncomplicated pachychoroid (UCP). Pachychoroid pigment epitheliopathy (PPE) was detected in five tamoxifen-group patients (11.3%). Patients with PPE in one eye had UCP in the fellow eye. Central serous chorioretinopathy findings were observed in one patient. Tamoxifen users had statistically lower GCC thickness in all inner rings of the ETDRS inlay and in the nasal outer ring only (p = 0.027, 0.002, 0.002, 0.001, and 0.030, respectively). No statistically significant difference in mean subfoveal PROS length was found between the groups. Conclusions: SD-OCT provides valuable information for identifying structural changes and evaluating ocular findings in patients receiving tamoxifen therapy. Increased choroidal thickness, PPE and thinning GCC were detected in tamoxifen users. These OCT findings may be an early indicator of retinal toxicity for patients undergoing tamoxifen therapy in the follow-up period.
- 10 March 2020
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 39 (2) , 115-121
Retinal structural changes in patients receiving tamoxifen therapy by spectral-domain optical coherence tomography
Purpose: To evaluate choroidal thickness, ganglion cell complex (GCC) and photoreceptor outer segment (PROS) length were measured in patients with breast cancer undergoing tamoxifen therapy, using spectral-domain optical coherence tomography (SD-OCT); results were compared with those for normal eyes. Materials and Methods: Forty-four patients with breast cancer, undergoing tamoxifen therapy, and 41 healthy controls were included in this prospective, comparative study. All participants underwent a complete ophthalmologic evaluation and SD-OCT. Subfoveal, nasal (nasal distance to fovea 500, 1000, 1500 μm), and temporal (temporal distance to fovea 500, 1000, 1500 μm) choroidal thickness measurements were performed using the enhanced depth imaging mode of SD-OCT. Using an Early Treatment Diagnostic Retinopathy Study (ETDRS) circle at the macular level, the automated retinal segmentation software was applied to determine the thickness of the GCC. PROS length was determined manually, as the distance from the inner surface of the ellipsoid zone to the inner surface of retina pigment epithelium. Results: The mean choroidal thickness was statistically greater in the tamoxifen group than controls in all quadrants (p < 0.001 for all quadrants). Of all tamoxifen users (44 eyes of 44 patients), 33 eyes (75%) had uncomplicated pachychoroid (UCP). Pachychoroid pigment epitheliopathy (PPE) was detected in five tamoxifen-group patients (11.3%). Patients with PPE in one eye had UCP in the fellow eye. Central serous chorioretinopathy findings were observed in one patient. Tamoxifen users had statistically lower GCC thickness in all inner rings of the ETDRS inlay and in the nasal outer ring only (p = 0.027, 0.002, 0.002, 0.001, and 0.030, respectively). No statistically significant difference in mean subfoveal PROS length was found between the groups. Conclusions: SD-OCT provides valuable information for identifying structural changes and evaluating ocular findings in patients receiving tamoxifen therapy. Increased choroidal thickness, PPE and thinning GCC were detected in tamoxifen users. These OCT findings may be an early indicator of retinal toxicity for patients undergoing tamoxifen therapy in the follow-up period.
- 1 March 2020
- Published by Kare Publishing in European Archives of Medical Research
- Vol. 36 (1) , 67-72
Comparison of Short-term Efficacy of Ranibizumab to Dexamethasone in the Treatment Naive Pseudophakic Diabetic Macular Edema: A Real-Life Study
- 1 March 2020
- Published by Kare Publishing in European Archives of Medical Research
- Vol. 36 (1) , 67-72
Comparison of Short-term Efficacy of Ranibizumab to Dexamethasone in the Treatment Naive Pseudophakic Diabetic Macular Edema: A Real-Life Study
- Open Access
- 1 January 2020
- Published by Kare Publishing in Haydarpasa Numune Training and Research Hospital Medical Journal
- Vol. 60 (3)
Long Term Visual Outcomes of Uveitis Associated with Behcet’s Disease
- 1 January 2020
- Published by Kare Publishing in Haydarpasa Numune Training and Research Hospital Medical Journal
- Vol. 60 (3)
Open AccessLong Term Visual Outcomes of Uveitis Associated with Behcet’s Disease
- Open Access
- 31 October 2019
- Published by Hindawi Limited in Journal of Ophthalmology
- Vol. 2019, 1-6
Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study
Purpose. To compare one-year treatment outcomes of intravitreal aflibercept (IVA) and intravitreal ranibizumab (IVR) for treatment of myopic choroidal neovascularization (mCNV). Methods. The medical records of a total of 30 eyes diagnosed with mCNV and underwent IVA or IVR treatment for a minimum one-year follow-up were studied retrospectively. All the subjects had an axial length >26 mm and received a 1 + PRN (pro re nata) regimen IVA or IVR. Best-corrected visual acuity (BCVA) and central macular thicknesses (CMT) on optical coherence tomography were evaluated before and after treatment. Results. There were 12 eyes in IVA group, with a mean age of 60.0 ± 10.2 years. The mean BCVA significantly improved from baseline 1.54 ± 0.76 to 0.85 ± 0.61 and the mean CMT significantly decreased from baseline 384.3 ± 119.1 μm to 305.9 ± 75.4 μm at Month 12 ( and , respectively). There were 18 eyes in IVR group, with a mean age of 57.4 ± 13.1 years. The mean BCVA improved from baseline 1.14 ± 0.90 to 1.04 ± 0.93 and the mean CMT significantly decreased from baseline 366.5 ± 102.3 μm to 323.6 ± 103.6 μm at Month 12 after IVR ( and , respectively). There was no significant difference between the groups in CMT changes in the study period (), but IVA resulted in significantly better final visual gain (0.69 versus 0.09; ). Conclusions. Both IVA and IVR treatment modalities resulted in similar anatomical outcomes but IVA had better visual outcomes in treatment of mCNV.- 31 October 2019
- Published by Hindawi Limited in Journal of Ophthalmology
- Vol. 2019, 1-6
Open AccessComparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study
Purpose. To compare one-year treatment outcomes of intravitreal aflibercept (IVA) and intravitreal ranibizumab (IVR) for treatment of myopic choroidal neovascularization (mCNV). Methods. The medical records of a total of 30 eyes diagnosed with mCNV and underwent IVA or IVR treatment for a minimum one-year follow-up were studied retrospectively. All the subjects had an axial length >26 mm and received a 1 + PRN (pro re nata) regimen IVA or IVR. Best-corrected visual acuity (BCVA) and central macular thicknesses (CMT) on optical coherence tomography were evaluated before and after treatment. Results. There were 12 eyes in IVA group, with a mean age of 60.0 ± 10.2 years. The mean BCVA significantly improved from baseline 1.54 ± 0.76 to 0.85 ± 0.61 and the mean CMT significantly decreased from baseline 384.3 ± 119.1 μm to 305.9 ± 75.4 μm at Month 12 ( and , respectively). There were 18 eyes in IVR group, with a mean age of 57.4 ± 13.1 years. The mean BCVA improved from baseline 1.14 ± 0.90 to 1.04 ± 0.93 and the mean CMT significantly decreased from baseline 366.5 ± 102.3 μm to 323.6 ± 103.6 μm at Month 12 after IVR ( and , respectively). There was no significant difference between the groups in CMT changes in the study period (), but IVA resulted in significantly better final visual gain (0.69 versus 0.09; ). Conclusions. Both IVA and IVR treatment modalities resulted in similar anatomical outcomes but IVA had better visual outcomes in treatment of mCNV. - Open Access
- 12 October 2019
- Published by Springer Nature in Research Square
Choroidal thickness, ganglion cell complex, and photoreceptor outer segment length evaluation in patients receiving tamoxifen therapy by spectral domain optical coherence tomography
Background To evaluate choroidal thickness, ganglion cell complex (GCC) and photoreceptor outer segment length were measured in patients with breast cancer undergoing tamoxifen therapy, using spectral-domain optical coherence tomography (SD-OCT); results were compared with those for normal eyes. Methods Forty-four patients with breast cancer, undergoing tamoxifen therapy, and 41 healthy controls were included in this prospective, comparative study. All participants underwent a complete ophthalmologic evaluation and SD-OCT. Subfoveal, nasal (nasal distance to fovea 500, 1000, 1500 μm), and temporal (temporal distance to fovea 500, 1000, 1500 μm) choroidal thickness measurements were performed using the enhanced depth imaging mode of SD-OCT. Using an Early Treatment Diagnostic Retinopathy Study (ETDRS) circle at the macular level, the automated retinal segmentation software was applied to determine the thickness of the GCC. The photoreceptor outer segment (PROS) length was determined manually, as the distance from the inner surface of the ellipsoid zone to the inner surface of retina pigment epithelium. Results The mean choroidal thickness was statistically greater in the tamoxifen group than controls in all quadrants ( p < 0.001 for all quadrants). Of all tamoxifen users (44 eyes of 44 patients), 33 eyes (75%) had UCP. Pachychoroid pigment epitheliopathy (PPE) was detected in five tamoxifen-group patients (11.3%). Patients with PPE in one eye had UCP in the fellow eye. Central serous chorioretinopathy findings were observed in one patient. Tamoxifen users had statistically lower GCC thickness in all inner rings of the ETDRS inlay and in the nasal outer ring only ( p = 0.027, 0.002, 0.002, 0.001, and 0.030, respectively). No statistically significant difference in mean subfoveal PROS length was found between the groups. Conclusions SD-OCT provides valuable information for identifying structural changes and evaluating ocular findings in patients receiving tamoxifen therapy. Increased choroidal thickness, PPE and thinning GCC were detected in tamoxifen users. These OCT findings may be an early indicator of retinal toxicity for patients undergoing tamoxifen therapy in the follow-up period. Keywords tamoxifen retinopathy, choroidal thickness, ganglion cell complex, PROS, spectral-domain optical coherence tomography
- 12 October 2019
- Published by Springer Nature in Research Square
Open AccessChoroidal thickness, ganglion cell complex, and photoreceptor outer segment length evaluation in patients receiving tamoxifen therapy by spectral domain optical coherence tomography
Background To evaluate choroidal thickness, ganglion cell complex (GCC) and photoreceptor outer segment length were measured in patients with breast cancer undergoing tamoxifen therapy, using spectral-domain optical coherence tomography (SD-OCT); results were compared with those for normal eyes. Methods Forty-four patients with breast cancer, undergoing tamoxifen therapy, and 41 healthy controls were included in this prospective, comparative study. All participants underwent a complete ophthalmologic evaluation and SD-OCT. Subfoveal, nasal (nasal distance to fovea 500, 1000, 1500 μm), and temporal (temporal distance to fovea 500, 1000, 1500 μm) choroidal thickness measurements were performed using the enhanced depth imaging mode of SD-OCT. Using an Early Treatment Diagnostic Retinopathy Study (ETDRS) circle at the macular level, the automated retinal segmentation software was applied to determine the thickness of the GCC. The photoreceptor outer segment (PROS) length was determined manually, as the distance from the inner surface of the ellipsoid zone to the inner surface of retina pigment epithelium. Results The mean choroidal thickness was statistically greater in the tamoxifen group than controls in all quadrants ( p < 0.001 for all quadrants). Of all tamoxifen users (44 eyes of 44 patients), 33 eyes (75%) had UCP. Pachychoroid pigment epitheliopathy (PPE) was detected in five tamoxifen-group patients (11.3%). Patients with PPE in one eye had UCP in the fellow eye. Central serous chorioretinopathy findings were observed in one patient. Tamoxifen users had statistically lower GCC thickness in all inner rings of the ETDRS inlay and in the nasal outer ring only ( p = 0.027, 0.002, 0.002, 0.001, and 0.030, respectively). No statistically significant difference in mean subfoveal PROS length was found between the groups. Conclusions SD-OCT provides valuable information for identifying structural changes and evaluating ocular findings in patients receiving tamoxifen therapy. Increased choroidal thickness, PPE and thinning GCC were detected in tamoxifen users. These OCT findings may be an early indicator of retinal toxicity for patients undergoing tamoxifen therapy in the follow-up period. Keywords tamoxifen retinopathy, choroidal thickness, ganglion cell complex, PROS, spectral-domain optical coherence tomography
- 12 September 2019
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 38 (4) , 401-405
Comparison of the short-term effect of aflibercept and dexamethasone implant on serous retinal detachment in the treatment of naive diabetic macular edema
Purpose: The aim of this study is to compare the efficacy of intravitreal injection of aflibercept and dexamethasone implant in the early treatment period of naive diabetic macular edema (DME) with serous retinal detachment (SRD). Materials and Methods: In this retrospective comparative study, medical records of patients who received treatment for naive DME with SRD and underwent three monthly intravitreal aflibercept (IVA) injections (2 mg) or one intravitreal dexamethasone implant (IDI) injection (0.7 mg) were reviewed. The best corrected visual acuity (BCVA), central macular thickness (CMT), and presence and height of SRD were compared three months after IDI injection and one month after the third IVA injection. Results: A total of 57 eyes of 49 patients were included in the study. The IVA group consisted of 32 eyes of 27 patients, whereas the IDI group consisted of 25 eyes of 22 patients. Both groups were similar in terms of gender, baseline intraocular pressure, HbA1c levels, types of diabetes, BCVA, CMT, and height of SRD (p = 0.469, p = 0.089, p = 0.889, p = 0.461, p = 0.072, p = 0.073, and p = 0.064, respectively). The mean CMT changes were 228.6 ± 109.8 µm and 168.5 ± 106.4 µm in the IDI and IVA groups, respectively (p < 0.001 for both groups). The change in CMT was statistically significantly greater in IDI group than in IVA group (p = 0.041). The mean SRD changes were 162.7 ± 106.9 µm and 110.7 ± 51.9 µm in the IDI and IVA groups, respectively (p < 0.001 for both groups), and the change in SRD height was statistically significantly greater in IDI group than in IVA group (p = 0.019). SRD completely resolved in 92% and 91.2% of the patients in IDI and IVA groups, respectively (p = 0.856). Moreover, BCVA was significantly increased after the injections in both groups (p < 0.001 for both groups), and the change in BCVA was comparable between the groups (p = 0.245). Conclusions: Fewer injections of dexamethasone implant demonstrated better morphological results than aflibercept in the early treatment period of naive diabetic macular edema (DME) with serous retinal detachment (SRD).
- 12 September 2019
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 38 (4) , 401-405
Comparison of the short-term effect of aflibercept and dexamethasone implant on serous retinal detachment in the treatment of naive diabetic macular edema
Purpose: The aim of this study is to compare the efficacy of intravitreal injection of aflibercept and dexamethasone implant in the early treatment period of naive diabetic macular edema (DME) with serous retinal detachment (SRD). Materials and Methods: In this retrospective comparative study, medical records of patients who received treatment for naive DME with SRD and underwent three monthly intravitreal aflibercept (IVA) injections (2 mg) or one intravitreal dexamethasone implant (IDI) injection (0.7 mg) were reviewed. The best corrected visual acuity (BCVA), central macular thickness (CMT), and presence and height of SRD were compared three months after IDI injection and one month after the third IVA injection. Results: A total of 57 eyes of 49 patients were included in the study. The IVA group consisted of 32 eyes of 27 patients, whereas the IDI group consisted of 25 eyes of 22 patients. Both groups were similar in terms of gender, baseline intraocular pressure, HbA1c levels, types of diabetes, BCVA, CMT, and height of SRD (p = 0.469, p = 0.089, p = 0.889, p = 0.461, p = 0.072, p = 0.073, and p = 0.064, respectively). The mean CMT changes were 228.6 ± 109.8 µm and 168.5 ± 106.4 µm in the IDI and IVA groups, respectively (p < 0.001 for both groups). The change in CMT was statistically significantly greater in IDI group than in IVA group (p = 0.041). The mean SRD changes were 162.7 ± 106.9 µm and 110.7 ± 51.9 µm in the IDI and IVA groups, respectively (p < 0.001 for both groups), and the change in SRD height was statistically significantly greater in IDI group than in IVA group (p = 0.019). SRD completely resolved in 92% and 91.2% of the patients in IDI and IVA groups, respectively (p = 0.856). Moreover, BCVA was significantly increased after the injections in both groups (p < 0.001 for both groups), and the change in BCVA was comparable between the groups (p = 0.245). Conclusions: Fewer injections of dexamethasone implant demonstrated better morphological results than aflibercept in the early treatment period of naive diabetic macular edema (DME) with serous retinal detachment (SRD).
- 1 September 2019
- Published by Kare Publishing in European Archives of Medical Research
- Vol. 35 (3) , 170-174
Comparison of Efficacy of Intravitreal Aflibercept and Ranibizumab in Treatment-naive Diabetic Macular Edema
- 1 September 2019
- Published by Kare Publishing in European Archives of Medical Research
- Vol. 35 (3) , 170-174
Comparison of Efficacy of Intravitreal Aflibercept and Ranibizumab in Treatment-naive Diabetic Macular Edema
- 14 August 2019
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 27 (8) , 1235-1241
The Efficacy of Posterior Subtenon Triamcinolone Acetonide Injection in Treatment of Irvine-Gass Syndrome
Purpose: To evaluate the efficacy and safety of posterior 40 mg subtenon triamcinolone acetonide (PST) injection in treating Irvine-Gass syndrome. Methods: The retrospective study included 21 patients (mean age: 76 ± 8.2) with a treatment-naïve eye subjected to topical anesthesia and injection of 40 mg/ml triamcinolone via a blunt tip SubTenon cannula through a single inferonasal peritomy. Best corrected visual acuity (BCVA; logMAR), intraocular pressure (IOP), biomicroscopic and funduscopic findings, and optical coherence tomography (OCT) measurements were recorded. Results: Baseline central macular thickness decreased from 431 ± 136 µm to 300 ± 67 µm (1st month; p = .002), to 292 ± 56 µm (3rd month; p = .002), and to 299 ± 66 µm (6th month; p = .005). Mean BCVA increased from 0.71 ± 0.23 to 0.27 ± 0.11, 0.19 ± 0.06, and 0.24 ± 0.17, respectively (all visits; p < 0.001). Mean IOP values did not change significantly (p = .12). Conclusion: PST injection is an effective and safe treatment for Irvine-Gass syndrome.
- 14 August 2019
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 27 (8) , 1235-1241
The Efficacy of Posterior Subtenon Triamcinolone Acetonide Injection in Treatment of Irvine-Gass Syndrome
Purpose: To evaluate the efficacy and safety of posterior 40 mg subtenon triamcinolone acetonide (PST) injection in treating Irvine-Gass syndrome. Methods: The retrospective study included 21 patients (mean age: 76 ± 8.2) with a treatment-naïve eye subjected to topical anesthesia and injection of 40 mg/ml triamcinolone via a blunt tip SubTenon cannula through a single inferonasal peritomy. Best corrected visual acuity (BCVA; logMAR), intraocular pressure (IOP), biomicroscopic and funduscopic findings, and optical coherence tomography (OCT) measurements were recorded. Results: Baseline central macular thickness decreased from 431 ± 136 µm to 300 ± 67 µm (1st month; p = .002), to 292 ± 56 µm (3rd month; p = .002), and to 299 ± 66 µm (6th month; p = .005). Mean BCVA increased from 0.71 ± 0.23 to 0.27 ± 0.11, 0.19 ± 0.06, and 0.24 ± 0.17, respectively (all visits; p < 0.001). Mean IOP values did not change significantly (p = .12). Conclusion: PST injection is an effective and safe treatment for Irvine-Gass syndrome.
- 21 June 2019
- Published by Kare Publishing in European Archives of Medical Research
- Vol. 35 (2) , 111-112
Bilateral Central Retinal Vein Occlusion Secondary to Essential Hypertension
- 21 June 2019
- Published by Kare Publishing in European Archives of Medical Research
- Vol. 35 (2) , 111-112
Bilateral Central Retinal Vein Occlusion Secondary to Essential Hypertension